150943-50-3

Basic information

• Product Name: 4-CHLORO-5-NITROPYRIMIDINE
• Synonyms: 4-CHLORO-5-NITROPYRIMIDINE;PYRIMIDINE, 4-CHLORO-5-NITRO-;4-Cloro-5-nitropyrimidine
• CAS NO: 150943-50-3
• Molecular Formula: C₄H₂ClN₃O₂
• Molecular Weight: 159.53
• Mol File: 150943-50-3.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 291.3±20.0 °C(Predicted)
• Appearance: /
• Density: 1.600±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -3.17±0.16(Predicted)
• CAS DataBase Reference: 4-CHLORO-5-NITROPYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-5-NITROPYRIMIDINE(150943-50-3)
• EPA Substance Registry System: 4-CHLORO-5-NITROPYRIMIDINE(150943-50-3)

Safety Data

• Hazardous Substances Data: 150943-50-3(Hazardous Substances Data)

Usage

General Description

4-Chloro-5-Nitropyrimidine is a chemical compound with the molecular formula C4H2ClN3O2. It belongs to the class of organic compounds known as chloropyrimidines, which are compounds containing a pyrimidine ring which bears a chlorine atom. This chemical is typically used in scientific research as a reagent or intermediate compound. It's often involved in the synthesis of various pharmaceuticals and complex organic molecules. While it's considered relatively stable under normal temperatures and pressures, the 4-Chloro-5-Nitropyrimidine's safety characteristics, including possible health hazards and environmental impact, have not been thoroughly studied. Thus, it should always be handled with appropriate safety measures in a controlled environment.

Upstream product

• 3749-47-1 4-hydroxyl-5-nitropyrimidine 

Downstream Products

• 1353677-33-4 N-(5-nitropyrimidin-4-yl)benzene-1,4-diamine 

Relevant articles and documents

Synthesis and characterization of novel pyrimidine-4,5-diamine as anticancer agent

Unlike latent cells, cancer cells supply deoxyribonucleoside triphosphates to cells continuously and thereby, prop up the uncontrolled cancer growth. Pyrimidine has been concerned in the separation of leukemic cells, known as adenine bioisosteres, as well as its biological activities, especially its anticancer properties. In this context, a novel series of N5-(3-substituted benzylidene)-N4-phenyl pyrimidine-4,5-diamine [5A-5F] / N5-(2-substituted benzylidene)-N2,N2-dimethyl-N4-phenyl pyrimidine-2,4,5-triamine [5a-5f] were synthesized by using the starting ingredient formimidamide/4(dimethylamino) benzimidamide and sodium ethoxide. The synthesized compounds were characterized by IR,1H NMR, and Mass spectral analyses and screened for their biological studies. In the present study, pyrimidine derivatives and their insilico modeling were done by using c-Src kinase and p38 MAP kinase complex followed by the evaluation of their anticancer activity. The screening of synthesized scaffolds possessed significant activity against HeLa cell lines and showed similar activity compared to standard Cisplatin. Among all the synthesized compounds, N5-(4-hydroxybenzylidene)-N4-phenyl pyrimidine-4,5-diamine 5A, N5benzylidene-N4-phenylpyrimidine-4,5-diamine 5C, N5-benzylidene-N2, N2-dimethyl-N4-phenyl pyrimidine-2,4,5-triamine 5c, and N5-(4-methoxy benzylidene)-N4-phenyl pyrimidine-4,5-diamine 5E showed the highest significant anticancer activity.

FUSED HETEROCYCLIC COMPOUNDS

The present invention provides a compound which has the effect of PDE inhibition, and which is useful as an agent for preventing or treating schizophrenia. The compound is represented by the formula (I): wherein the symbols are defined in the specification.